ConductScience.org, home

Disease · MONDO_0005582

Comparisons in its trials18

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Stepped-care vs Standard Care: Number of Subjects Who Reached Binge Eating Remission65 of 15216 of 39191NCT00829283Trial comparisons
Stepped-care vs Standard Care: serious adverse events0 of 1520 of 39191NCT00829283Trial comparisons
NB Medication vs Placebo: deaths from any cause0 of 320 of 3466NCT03047005Trial comparisons
NB Medication vs Placebo: serious adverse events0 of 320 of 3466NCT03047005Trial comparisons
Bupropion vs Placebo: serious adverse events0 of 310 of 3061NCT00414167Trial comparisons
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml vs Placebo: deaths from any cause0 of 190 of 1736NCT03279731Trial comparisons
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml vs Placebo: serious adverse events2 of 191 of 1736NCT03279731Trial comparisons
On-going Blinded Pharmacotherapy (NB) vs On-going Blinded Pharmacotherapy (Placebo): deaths from any cause0 of 150 of 1631NCT03063606Trial comparisons
On-going Blinded Pharmacotherapy (NB) vs On-going Blinded Pharmacotherapy (Placebo): serious adverse events0 of 150 of 1631NCT03063606Trial comparisons
Naltrexone/ Bupropion Combination vs Pill Placebo: deaths from any cause0 of 110 of 819NCT02317744Trial comparisons
Naltrexone/ Bupropion Combination vs Pill Placebo: serious adverse events0 of 110 of 819NCT02317744Trial comparisons
OTC Orlistat + Guided Self-help Affect Regulation vs OTC Orlistat /Medication Management Alone: serious adverse events0 of 80 of 917NCT00601354Trial comparisons
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml vs Placebo: Remission From Binge-eating3 of 74 of 815NCT03279731Trial comparisons
Naltrexone/Bupropion vs Placebo: Binge-Eating Remission1 of 10 of 23NCT03946111Trial comparisons
Naltrexone/Bupropion vs Placebo: deaths from any cause0 of 10 of 23NCT03946111Trial comparisons
Naltrexone/Bupropion vs Placebo: Binge-Eating Remission1 of 12 of 23NCT03946111Trial comparisons
Naltrexone/Bupropion vs Placebo: Binge-Eating Remission0 of 11 of 23NCT03946111Trial comparisons
Naltrexone/Bupropion vs Placebo: serious adverse events0 of 10 of 23NCT03946111Trial comparisons

diseases-2026-09-18-0.1.0

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005582/comparisons